2Rognoni A,Lupi A,Lazzero M,et al.Levosimendan:from basic science to clinical trials. Recent Pat Cardiovasc Drug Discov,2011,6:9-15.
3Innes CA,Wagstaff AJ.Levosimendan:a review of its use in the management of acute decompensated heart failure.Drugs,2003,63:2651-2671.
4Follath F,Cleland JG,Just H,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study):a randomised double-blind trial.Lancet,2002,360:196-202.
5Nieminen MS,Akkila J,Hasenfuss G,et al.Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.J Am Coll Cardiol,2000,36:1903-1912.
6Mebazaa A,Nieminen M,Packer M,et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure:the SURVIVE randomized trial.JAMA,2007,297:1883-1891.
7Parissis JT,Panou F,Farmakis D,et al.Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.Am J Cardiol,2005,96:423-426.
8Rognoni A,Lupi A,Lazzero M,et al.Levosimendan:from basic science to clinical trials. Recent Pat Cardiovasc Drug Discov,2011,6:9-15.
9Mebazaa A,Nieminen M,Packer M,et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure:the SURVIVE randomized trial.JAMA,2007,297:1883-1891.
10Krell MJ,Kline EM,Bates ER,et al.Intermittent,ambulatory dobutamine infusion in severe heart failure.Am Heart J,1986,112:787-791.
4Stavrakis S, Pakala A, Thomas J, et al. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function[J]. American Med Sci, 2013, 345(3): 211-217.
5Luecke T, Pelosi P. Clineal review: positive end-expirtory pressure and cardiac output[J]. Crit Care Med, 2005, 9(6): 607-621.
6De Luca L, Sardella G, Proietti P, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echoeardiographic study [J]. J Am Soc Echocardiogr, 2006, 19 (2): 172-177.
7Alibaz-Oner F, Gurbuz OZ, Oner E, etal. Impact of levosimendan on right ventricular functions by us-ing novel tissue Doppler derived indices in patients with ischaemic left ventricular failure[J]. Kardiol Pol, 2013, 71(10): 1036-1041.
8Obermuller N, Geiger H, Weipert C, et al. Current developments in early diagnosis of acute kidney injury[J]. Int Urol Nephrol, 2014, 46(1): 1-7.
9Park M, Vittinghoff E, Liu KD, et al. Urine biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have different patterns in heart failure Exacerbation[J]. Biomarker insights, 2013, 8(3): 15-18.
10Alvelos M, Loureno P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure [J].Int Urol Nephrol, 2013,165(1): 51-55.
